tiprankstipranks
Trending News
More News >
MRT Inc. (JP:6034)
:6034
Japanese Market
Advertisement

MRT Inc. (6034) AI Stock Analysis

Compare
0 Followers

Top Page

JP:6034

MRT Inc.

(6034)

Select Model
Select Model
Select Model
Neutral 53 (OpenAI - 4o)
Rating:53Neutral
Price Target:
¥723.00
▲(2.26% Upside)
The overall stock score is primarily influenced by financial performance challenges, including declining revenue and profitability. Technical analysis provides some positive signals, but valuation remains a significant concern due to negative earnings and lack of dividend yield.

MRT Inc. (6034) vs. iShares MSCI Japan ETF (EWJ)

MRT Inc. Business Overview & Revenue Model

Company DescriptionMRT Inc. operates a medical information platform. The company provides temporary and part-time doctor services; doctor's career change support service; Door., an app to connect network of doctors; Door.into, which provides online health counseling, and online medical care; Pocket Doctor, a telemedicine/health consultation app; groupware for medical offices; FASTCALL that consolidates the functions required for hospital crisis management system as safety confirmation service for medical institution; and Good Doctors, which provides owned media sent by doctors. It also offers nurse and pharmacist recruitment service; human resources introduction service for clinical laboratory engineers, radiologists, and dialysis nurses, as well as for new business openings and succession projects; and recruitment information service for exclusive industrial physicians and contract industrial physicians. In addition, the company engages in employment agency business, opening of business, business succession support business, and PR business, and career support business. Further, it offers services for supporting the operation of medical institutions, such as fund management, utilizing medical fee factoring, payroll calculation for doctors' part-time jobs, and payroll transfer agency services. Additionally, the company sells human umbilical cord-derived stem cell culture supernatant; and provides babysitter services, tax accountant referral service, credit card payment agency service, questionnaire survey request for pharmaceuticals, etc., as well as media coverage cooperation, lecture request, event rescue, etc. It also publishes books on illness and treatment; and offers health maintenance service and member comprehensive compensation systems. The company was formerly known as Medical Research and Technology Co., Ltd and changed its name to MRT Inc. in September 2014. MRT Inc. was incorporated in 2000 and is headquartered in Tokyo, Japan.
How the Company Makes MoneyMRT Inc. generates revenue through its digital platforms that offer a range of services including job placement and recruitment services for medical professionals, advertising and promotional services for healthcare products, and subscription fees for access to specialized medical information. The company partners with healthcare institutions, medical device manufacturers, and pharmaceutical companies to create a robust ecosystem that supports its monetization strategies. Additional revenue streams may include consulting and support services tailored to the needs of healthcare providers.

MRT Inc. Financial Statement Overview

Summary
MRT Inc. is facing financial difficulties with declining revenue and profitability. The income statement shows negative net profit and EBIT margins, and cash flow analysis reveals a significant decline in free cash flow growth. The balance sheet is stable but profitability issues persist.
Income Statement
45
Neutral
MRT Inc. shows a concerning decline in revenue and profitability over the recent periods. The TTM data indicates a negative net profit margin of -8.26%, and EBIT margin of -4.15%, reflecting operational challenges. Despite a slight revenue growth of 1.11% in the TTM, the company has faced significant revenue declines in prior years, impacting overall performance.
Balance Sheet
60
Neutral
The balance sheet reflects a moderate debt-to-equity ratio of 0.16 in the TTM, indicating manageable leverage. However, the return on equity is negative at -7.77%, highlighting profitability issues. The equity ratio remains stable, suggesting a solid capital structure despite recent financial challenges.
Cash Flow
50
Neutral
Cash flow analysis reveals a significant decline in free cash flow growth at -56.11% in the TTM, raising concerns about cash generation capabilities. The operating cash flow to net income ratio is 0.58, indicating some operational cash flow support, but overall cash flow performance has weakened.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue4.27B4.17B5.41B8.74B4.47B2.56B
Gross Profit2.75B2.74B3.27B5.60B3.55B1.76B
EBITDA174.66M139.00M1.10B3.16B1.45B420.18M
Net Income-265.63M-309.16M517.00M2.16B774.49M131.81M
Balance Sheet
Total Assets6.29B6.75B6.47B8.16B4.98B3.31B
Cash, Cash Equivalents and Short-Term Investments2.19B2.62B3.78B4.90B1.03B1.59B
Total Debt646.35M1.05B641.00M875.86M1.04B1.11B
Total Liabilities1.79B2.12B1.76B3.67B2.69B1.75B
Stockholders Equity4.39B4.52B4.58B4.39B2.22B1.52B
Cash Flow
Free Cash Flow214.58M462.00M-208.00M4.43B-405.64M183.97M
Operating Cash Flow231.74M503.04M-193.00M4.51B-298.89M294.97M
Investing Cash Flow-2.00B-1.84B-243.61M-431.11M-206.51M-64.61M
Financing Cash Flow-194.10M161.77M-669.19M-203.98M-67.49M-397.41M

MRT Inc. Technical Analysis

Technical Analysis Sentiment
Negative
Last Price707.00
Price Trends
50DMA
708.52
Negative
100DMA
715.24
Negative
200DMA
707.34
Negative
Market Momentum
MACD
-0.46
Positive
RSI
45.97
Neutral
STOCH
35.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:6034, the sentiment is Negative. The current price of 707 is below the 20-day moving average (MA) of 713.00, below the 50-day MA of 708.52, and below the 200-day MA of 707.34, indicating a bearish trend. The MACD of -0.46 indicates Positive momentum. The RSI at 45.97 is Neutral, neither overbought nor oversold. The STOCH value of 35.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:6034.

MRT Inc. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
85
Outperform
8.83B13.6313.65%8.17%26.12%38.78%
74
Outperform
3.52B15.6915.49%1.83%5.27%12.22%
53
Neutral
¥3.94B
-2.66%-913.85%
44
Neutral
2.71B-3.64-99.33%15.50%-31.31%
43
Neutral
23.44B-32.030.00%1.08%-0.58%-260.22%
40
Neutral
6.51B-2.16-1782.91%-2.60%-103.03%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
JP:6034
MRT Inc.
707.00
-134.00
-15.93%
JP:3628
Data Horizon Co., Ltd.
508.00
9.00
1.80%
JP:3671
Softmax Co., Ltd. (Japan)
372.00
164.60
79.36%
JP:3902
Medical Data Vision Co.Ltd.
596.00
115.39
24.01%
JP:4438
Welby Inc.
319.00
-98.00
-23.50%
JP:6545
internet infinity INC.
645.00
201.81
45.54%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Sep 18, 2025